Gustav Buescher

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Decompression of portal hypertension by transjugular intrahepatic portosystemic shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune dysfunction.

Decompression of portal hypertension by transjugular intrahepatic portosystemic shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune dysfunction.

Journal: Gut

Published: January 29, 2026

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Journal: Gut

Published: November 21, 2025

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 06, 2024

Current practice in the management of paediatric autoimmune liver disease in Europe.

Current practice in the management of paediatric autoimmune liver disease in Europe.

Journal: Journal of pediatric gastroenterology and nutrition

Published: January 17, 2024

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Journal: Frontiers in immunology

Published: January 12, 2024

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.

Journal: Frontiers in immunology

Published: October 22, 2023

Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis.

Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis.

Journal: Journal of autoimmunity

Published: June 11, 2023

Brain abscess as a complication of pulmonary manifestation of HHT

Brain abscess as a complication of pulmonary manifestation of HHT

Journal: Innere Medizin (Heidelberg, Germany)

Published: May 26, 2023

Severe acute hepatitis and acute liver failure of unknown origin in children: a questionnaire-based study within 34 paediatric liver centres in 22 European countries and Israel, April 2022.

Severe acute hepatitis and acute liver failure of unknown origin in children: a questionnaire-based study within 34 paediatric liver centres in 22 European countries and Israel, April 2022.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: May 13, 2022

Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey.

Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey.

Journal: Journal of hepatology

Published: April 21, 2022

SARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience.

SARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience.

Journal: Journal of pediatric gastroenterology and nutrition

Published: October 16, 2021

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era.

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era.

Journal: Scandinavian journal of gastroenterology

Published: May 19, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026